PMID- 35782343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 13
DP  - 2022
TI  - Elevated activating Fc gamma receptors levels correlated with susceptibility and 
      severity of IgA nephropathy.
PG  - 20406223221106878
LID - 10.1177/20406223221106878 [doi]
LID - 20406223221106878
AB  - BACKGROUND: It is still uncertain if a dysregulated expression of activating Fc 
      gamma receptors (FcgammaRs) is associated with the development of immunoglobulin A 
      nephropathy (IgAN). METHODS: RNA sequencing was used to determine the mRNA levels 
      of type I FcgammaRs, which were then verified by quantitative reverse 
      transcription-polymerase chain reaction (qRT-PCR). Commercial ELISA kits were 
      used to detect plasma soluble FcgammaRIIIb (sFcgammaRIIIb). RESULTS: We first examined 
      the expression of FcgammaRs genes in 17 patients with IgAN and six healthy controls. 
      The expression of FcgammaRIa, FcgammaRIb, FcgammaRIIa, FcgammaRIIc, FcgammaRIIIa, and FcgammaRIIIb was 
      shown to be higher in IgAN patients. Even without statistical significance, there 
      was a downward trend in FcgammaRIIb mRNA levels in IgAN. We observed that the 
      expression levels of activating FcgammaR mRNAs were consistently higher in an 
      independent set of 20 IgAN patients and 20 healthy controls, confirming the 
      RNA-seq results. FcgammaRIIIb was the IgG receptor with the greatest difference in 
      expression between the two groups (log(2) fold-change = 1.82). We observed a much 
      higher percent of FcgammaRIIIb positive cells in IgAN by flow cytometry. Next, we 
      measured plasma sFcRIIIb levels in 50 patients with IgAN and 50 healthy controls. 
      The findings revealed that the mean sFcgammaRIIIb level in plasma in participants 
      with IgAN was much higher than that of healthy controls. Increased sFcgammaRIIIb 
      levels were associated with a substantial increase in body mass index (BMI), 
      lipid levels, serum creatinine level, and a larger percentage of sclerosis 
      compared with lower sFcRIIIb levels. Patients in the group with higher sFcgammaRIIIb 
      levels were more likely to get glucocorticoid treatment. CONCLUSION: The results 
      demonstrated that the mRNA levels of the activating Fc receptor of IgG were 
      significantly increased in IgAN. Patients with higher plasma sFcgammaRIIIb levels may 
      have had more severe illness than those with lower levels.
CI  - (c) The Author(s), 2022.
FAU - Li, Hongfen
AU  - Li H
AD  - Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, 
      P.R. China.
FAU - Liu, Youxia
AU  - Liu Y
AUID- ORCID: 0000-0002-9058-0218
AD  - Department of Nephrology, Tianjin Medical University General Hospital, No. 154, 
      Anshan Road, Heping District, Tianjin 300052, P.R. China.
FAU - Yu, Huyan
AU  - Yu H
AD  - Department of Nephrology, Yunfu People's Hospital, Yunfu, Guangdong province, 
      P.R. China.
FAU - Wang, Fanghao
AU  - Wang F
AD  - Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, 
      P.R. China.
FAU - Jia, Junya
AU  - Jia J
AD  - Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, 
      P.R. China.
FAU - Yan, Tiekun
AU  - Yan T
AD  - Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, 
      P.R. China.
FAU - Lin, Shan
AU  - Lin S
AD  - Department of Nephrology, Tianjin Medical University General Hospital, No. 154, 
      Anshan Road, Heping District, Tianjin 300052, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20220627
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC9243373
OTO - NOTNLM
OT  - IgA nephropathy
OT  - activating Fc gamma receptors
OT  - disease severity
OT  - soluble FcgammaRIIIb
COIS- Conflict of interest statement: The authors declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2022/07/06 06:00
MHDA- 2022/07/06 06:01
PMCR- 2022/06/27
CRDT- 2022/07/05 09:49
PHST- 2022/03/27 00:00 [received]
PHST- 2022/05/19 00:00 [accepted]
PHST- 2022/07/05 09:49 [entrez]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/07/06 06:01 [medline]
PHST- 2022/06/27 00:00 [pmc-release]
AID - 10.1177_20406223221106878 [pii]
AID - 10.1177/20406223221106878 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2022 Jun 27;13:20406223221106878. doi: 
      10.1177/20406223221106878. eCollection 2022.